Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder.
Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder. Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder. Moneycontrol Latest News Read More
English 
हिन्दी